The Foods and Drug Administration said right now that subsequent yesterday’s good advisory committee assembly outcome about the Pfizer-BioNTech COVID-19 vaccine, it would fast perform towards finalization and issuance of an emergency use authorization for the COVID-19 vaccine.
The Fda gave no precise timeline.
The agency has also notified the U.S. Centers for Illness Command and Avoidance and Operation Warp Pace, so they can execute their designs for well timed vaccine distribution.
Understand on-demand from customers, receive credit rating, uncover products and alternatives. Get Started >>
Approval usually means vaccine distribution would be on Operation Warp Speed’s program for distribution to entrance-line healthcare staff and susceptible populations in lengthy-term treatment amenities by mid-month.
The Fda advisory committee has scheduled yet another assembly to review the Moderna vaccine on Thursday, December seventeen.
See our continuing vaccine coverage right here:
Pfizer-BioNTech vaccine gets Fda advisory committee approval
CMS provides assistance in billing Medicare for COVID-19 antibody procedure
Hundreds in the United Kingdom are the initial to acquire Pfizer COVID-19 vaccine
Eli Lilly and UnitedHealth Group lover on COVID-19 antibody procedure for higher-hazard individuals
Operation Warp Pace is looking to start off distributing COVID-19 vaccine by mid-month
Moderna seeks regulatory authorization for its COVID-19 vaccine
HHS will start off allocating Regeneron’s COVID-19 therapeutic this 7 days
HHS associates with chain and independent pharmacies to boost obtain to long term COVID-19 vaccines
COVID-19 vaccine distribution will start off inside 24 several hours of an emergency use authorization
Moderna vaccine applicant exhibits 94.5% efficacy towards COVID-19
Pfizer touts new COVID-19 vaccine, calling it ‘90% effective’
Medicare beneficiaries can get monoclonal antibody COVID-19 treatment plans at no value
Fda grants emergency use authorization for Eli Lilly antibody procedure for COVID-19
Electronic mail the author: [email protected]